956025-99-3

Usage

Uses

Used in Pharmaceutical Industry:
3-BrB-PP1 is used as a research tool for studying the role of Akt in cellular processes and its involvement in various diseases, particularly cancer. Its ability to inhibit Akt makes it a valuable compound for investigating the underlying mechanisms of Akt-dependent signaling pathways and their contribution to tumor growth and progression.
Used in Cancer Research:
3-BrB-PP1 is used as a potential therapeutic agent for targeting cancer cells with high Akt activity. By inhibiting Akt, it can disrupt the survival and growth signals in cancer cells, leading to cell cycle arrest and apoptosis. This makes 3-BrB-PP1 a promising candidate for the development of targeted cancer therapies, especially for cancers with known Akt overactivation.
Used in Drug Development:
3-BrB-PP1 is used as a lead compound in the development of novel Akt inhibitors for the treatment of various diseases, including cancer. Its structure and inhibitory properties serve as a foundation for designing and optimizing new compounds with improved potency, selectivity, and pharmacokinetic properties.
Used in Cellular Signaling Studies:
3-BrB-PP1 is used as a biochemical probe to dissect the complex network of signaling pathways regulated by Akt. By selectively inhibiting Akt, researchers can gain insights into the specific roles of Akt in cellular processes and identify potential targets for therapeutic intervention.

Upstream product

• 1428640-42-9 C₁₅H₁₇BrN₄ 
• 77287-34-4 formamide 
• 1364226-31-2 2-(methoxy-(3-bromobenzyl)methylene)malononitrile 
• 1878-67-7 3-Bromophenylacetic acid 
• 98288-51-8 2-(3-bromophenyl)acetyl chloride 

Relevant academic research and scientific papers

Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues

In this study, we set out to rationally optimize PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine derived compounds. Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD's natural ligand ATP. Therefore we suggest an alternate binding mode where the compounds are flipped 180 degrees. This possible alternate binding mode for pyrazolo[3,4-d]pyrimidine based compounds could pave the way for a new class of specific protein kinase inhibitors for kinases sensitive towards pyrazolo[3,4-d]pyrmidines.

Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by toxoplasma gondii

Toxoplasma gondii is sensitive to bulky pyrazolo [3,4-d] pyrimidine (PP) inhibitors due to the presence of a Gly gatekeeper in the essential calcium dependent protein kinase 1 (CDPK1). Here we synthesized a number of new derivatives of 3-methyl-benzyl-PP (3-MB-PP, or 1). The potency of PP analogues in inhibiting CDPK1 enzyme activity in vitro (low nM IC50 values) and blocking parasite growth in host cell monolayers in vivo (low μM EC 50 values) were highly correlated and occurred in a CDPK1-specific manner. Chemical modification of the PP scaffold to increase half-life in the presence of microsomes in vitro led to identification of compounds with enhanced stability while retaining activity. Several of these more potent compounds were able to prevent lethal infection with T. gondii in the mouse model. Collectively, the strategies outlined here provide a route for development of more effective compounds for treatment of toxoplasmosis and perhaps related parasitic diseases.

MODULATION OF PROTEIN TRAFFICKING

Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.

A small molecule inhibitor selective for a variant ATP-binding site of the chaperonin GroEL

The chaperonin GroEL is a megadalton-sized molecular machine that plays an essential role in the bacterial cell assisting protein folding to the native state through actions requiring ATP binding and hydrolysis. A combination of medicinal chemistry and genetics has been employed to generate an orthogonal pair, a small molecule that selectively inhibits ATPase activity of a GroEL ATP-binding pocket variant. An initial screen of kinase-directed inhibitors identified an active pyrazolo-pyrimidine scaffold that was iteratively modified and screened against a collective of GroEL nucleotide pocket variants to identify a cyclopentyl carboxamide derivative, EC3016, that specifically inhibits ATPase activity and protein folding by the GroEL mutant, I493C, involving a side chain positioned near the base of ATP. This orthogonal pair will enable in vitro studies of the action of ATP in triggering activation of GroEL-mediated protein folding and might enable further studies of GroEL action in vivo. The approach originated for studying kinases by Shokat and his colleagues may thus also be used to study large macromolecular machines.